Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2012

View Archived Issues

Skuldtech and AB Science identify new markers for pancreatic cancer survival

Eisai: second quarter of fiscal 2012 in review

Avaxia Biologics presents promising in vivo results for AVX-470m

Astellas Pharma presents overview of second quarter of fiscal 2012

Promising results reported from phase IIa trial of UISH-001

Two phase III trials of Epanova meet primary and secondary endpoints

FDA approves Pfizer's Xeljanz for rheumatoid arthritis

Takeda Pharmaceutical reviews accomplishments of second quarter of fiscal 2012

GlaxoSmithKline reports highlights of third quarter 2012

Novel strategies for lipid management: SOAT inhibitor PRD-017

Aspireo Pharmaceuticals begins phase IIa trial of Somatoprim

Novartis files for approval of QVA-149 in Japan

Cardiovascular benefits demonstrated for SIRT1 activator SRT-2104 in smokers

Bayer presents new protein kinase Akt inhibitors for cancer

Bristol-Myers Squibb patents new lysophospholipid receptor antagonists

Aileron Therapeutics develops new oncology drug candidate

Phase I trial of SMT-C1100 meets endpoints

Takeda Pharmaceutical synthesizes novel ionotropic glutamate receptor agonists

First patient enrolled in phase I/IIa trial of PAT-SM6

FDA advisory committee votes in favor of raxibacumab

Novel gamma-secretase inhibitors disclosed by Merck & Co.

FDA grants priority review to trastuzumab emtansine NDA

MorphoSys and Novartis expand antibody alliance

Pfizer patents novel Trk inhibitors for the treatment of pain

Cadila Pharmaceuticals presents clinical results for CADI-05 in bladder cancer

New nNOS inhibitors presented by Northwestern University

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...